EP2167109A2 - Materialzusammensetzungen, welche aus exokrinem drüsengewebe erhaltene adulte stammzellen enthalten, insbesondere zur verwendung in der regenerationsmedizin, z. b. zur wiederherstellung von verletztem oder geschädigtem myokardgewebe - Google Patents
Materialzusammensetzungen, welche aus exokrinem drüsengewebe erhaltene adulte stammzellen enthalten, insbesondere zur verwendung in der regenerationsmedizin, z. b. zur wiederherstellung von verletztem oder geschädigtem myokardgewebeInfo
- Publication number
- EP2167109A2 EP2167109A2 EP08784719A EP08784719A EP2167109A2 EP 2167109 A2 EP2167109 A2 EP 2167109A2 EP 08784719 A EP08784719 A EP 08784719A EP 08784719 A EP08784719 A EP 08784719A EP 2167109 A2 EP2167109 A2 EP 2167109A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- stem cells
- cells
- tissue
- material composition
- stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1329—Cardiomyocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Definitions
- compositions containing adult stem cells obtained from exocrine glandular tissue especially for use in regenerative medicine, e.g. to restore injured or damaged myocardial tissue
- Heart failure is a major cause of death in industrialized countries and is due to the inability of mature myocardial cells (cardiomyocytes) to divide and repair damaged heart muscle. Since the therapeutic use of embryonic cardiomyocytes is banned in most countries, adult human stem cells could be an alternative to regenerative medicine.
- Adult stem cells of various origins have already been injected intramyocardially to be transferred to cardiomyocytes. However, only in animal experiments did such cell-cell contact induce mesenchymal stem cells for differentiation into cardiomyocytes.
- the use of human cardiomyocytes from human adult stem cells to restore injured or damaged myocardium has been an objective for many years, but not yet optimally achieved.
- this object is fundamentally solved by providing a method for producing autonomously contracting cardiomyocytes by differentiation from adult stem cells isolated from exocrine glandular tissue and by the provision of special material compositions containing these stem cells.
- these compositions which include, for example, injectable cell compositions, may have the disadvantage that, while the cells either reach the desired site of application but do not remain there (eg, possible in the case of injection), or the material composition is relatively bulky, the desired absorption extended in the body and a larger footprint in the body with it (eg when using conventional solid substrates).
- the present invention is based on the finding that these disadvantages can be avoided by providing new material compositions according to claim 1 or claim 12, in which the stem cells are present on carrier matrices in the form of, preferably resorbable, thread structures or nets on which the stem cells for Differentiation, eg can be brought to autonomously contracting heart muscle cells.
- exocrine glandular tissue thus provides a very effective source for widely differentiable stem cells, from which the desired heart muscle cells can be obtained successfully in good yields in bulk.
- exocrine glandular tissue used according to the invention may be derived from an adult organism, juvenile organism or non-human fetal organism, preferably a post-mortem. native organism.
- adult as used in the present application thus refers to the developmental stage of the parent tissue and not to that of the donor organism from which the tissue is derived.
- Adult stem cells are non-embryonic stem cells.
- the exocrine glandular tissue is isolated from a salivary gland, lacrimal gland, sebaceous gland, sweat gland, genital glands, including the prostate, or from gastrointestinal tissue, including pancreas, or secretory tissue of the liver.
- this is acinar tissue.
- the acinar tissue is from the pancreas, parotid gland, or submandibular gland.
- the stem cells isolated primarily from the organism are used as a source for the further cultivation and differentiation towards heart muscle cells.
- This variant has the advantage of a particularly simple process control.
- the desired differentiated cells can be obtained directly from a primary culture.
- an aggregation of the stem cells isolated from the organism into so-called organoid bodies takes place.
- This variant has the advantage that with the organoid bodies an effective reservoir for larger amounts of differentiated cells is created.
- the inventors have found that the stem cells isolated from the exocrine glandular tissue form organoid bodies which, when supplied with nutrients, show a strong growth to tissue bodies with diameters of up to a few millimeters or more.
- this method can be carried out by identifying, if necessary, selecting and further multiplying myocardial cells, which have formed spontaneously from the primary or secondary (from the organoid bodies) isolated stem cells.
- a stimulation of the cell culture is provided in the differentiation of the heart muscle cells.
- the stimulation has the advantage of increased efficiency and speed of formation of the desired heart muscle cells.
- a first variant after the differentiation of the stem cells to the heart muscle cells, their stimulated propagation in a culture medium is provided.
- the stimulation already happens at an earlier stage and concerns the still undifferentiated stem cells whose development / differentiation is induced to the desired heart muscle cells.
- the stimulation may include one or more of the following stimulation treatments, which may be performed simultaneously or sequentially. Co-culture with differentiated myocardial cells or with cell lines derived therefrom, treatment (imprinting) with immobilized or dissolved molecular differentiation factors provided in the liquid phase, or gene activation in the stem cell may be provided. Furthermore, a stimulation, the addition of other substances, for For example, hormones (eg, insulin), or cell types that affect differentiation.
- hormones eg, insulin
- the carrier is, for example, a synthetic substrate which has advantages for a targeted design with the differentiation factors, or a biological cell on whose cell membrane the differentiation factors are arranged.
- Some exemplary, non-limiting growth and differentiation factors that can be used are 5 ⁇ -Azazytidin, bFGF, Cardiogenol, transferrin and PDGF.
- the stimulation treatment is carried out by cultivating the stem cells under normal conditions (eg as described in Example 1) in the presence of biological "nanostructured surfaces.”
- This term refers here to cells, for example cardiomyocytes or other cardiac cells, which are treated by a fixation treatment,
- the cell membrane was made opaque while retaining the surface structure of the cells, including the surface proteins and other molecules exposed there, thus affecting substances from within excluded from these cells and the stimulation is done specifically by the influence of the surface structure of the fixed cells.
- an identification and selection of the differentiated cells from the cell culture is provided, there may be advantages for the further use of the heart muscle cells formed.
- a cell composition can be provided which consists entirely or for the most part of heart muscle cells. If the selection is done with sorting, which are known per se, such. For example, with a preparative cell sorter method or a sorting in a fluidic microsystem, there may be advantages for compatibility with conventional cell biological procedures.
- a further advantage of identification and selection is that cells which are not identified as heart muscle cells and are not selected accordingly from the processed culture can be subjected to further cultivation and differentiation.
- the yield of the method can be increased.
- Sorts of sorting of cardiomyocytes and their progenitor cells would be e.g. by transfecting reporter gene constructs with cardiac-specific promoters, which give rise to fluorescent products when switched on, or fluorescently labeled antibodies to cardiac-specific proteins.
- stem cells are obtained from tissue of secretory glands or glands of the gastrointestinal tract of the organism to form the heart muscle cells.
- the stem cells are in particular isolated from tissue which consists of acinar tissue or contains acinar tissue.
- Preferred donor organisms are vertebrates, especially mammals. Especially preferred is the human.
- the isolation of the stem cells takes place from non-embryonic states, ie from differentiated tissue in the juvenile phase or the adult phase.
- differentiated tissue in the fetal state can in principle also be resorted to.
- the heart muscle cells produced are preferably used therapeutically.
- a particular advantage is that human heart muscle cells can be produced from non-embryonic stem cells and used for the treatment of humans.
- a particularly attractive option is the autologous treatment of a person with cardiomyocytes derived from their own stem cells. In this way, effective rejection reactions can be avoided.
- the treatment will involve the recovery of injured or damaged myocardium.
- the treatment may involve either the administration of the undifferentiated stem cells and their induced differentiation into myocardial cells in the body, or the administration of the already differentiated myocardial cells, e.g. in a transplant.
- an object of the invention are cell compositions which contain adult stem cells from differentiated exocrine glandular tissue and / or heart muscle cells resulting therefrom.
- the cell composition may contain other cells or materials which form eg a matrix.
- the cell composition may also comprise an envelope or a 3-dimensional matrix in which the heart muscle cells and optionally other cell types are arranged.
- the cladding or 3-dimensional matrix consists, for example, of alginate, collagen, implantable materials, polymers (biopolymers or synthetic polymers), in particular materials degradable in the body.
- the matrix may have a thread structure or network structure.
- a principal aspect of the present invention relates to a composition of matter wherein the glandular stem cells obtained from exocrine glandular tissue are on a support matrix having the form of sutures or nets.
- This carrier matrix is preferably biocompatible and degradable in the body. Typically, this is a resorbable plastic material, for example the commercially available Vicryl (ex Ethicon) or the above-mentioned polymeric materials.
- the glandular stem cells attach to both the outer surface and the microstructures of the threads and nets and can be differentiated there. With the help of this carrier matrix, the stem cells or the resulting differentiated cells can be conveniently and specifically brought to desired application sites in the body.
- a specific embodiment of the present invention relates to a Biodegradable Strain Cell Patch (BTS) for myocardial regeneration.
- BTS Biodegradable Strain Cell Patch
- Such a patch comprises adult stem cells from exocrine glandular tissue, preferably pancreatic stem cells, and a porous, optionally subdivided, matrix for receiving the cells, has a large contact area for the myocardial wound surface to which it is to be applied after removal of the epicardium, is usually multi-layered, for example composed of several sponge-like membranes, but relatively thin (low diffusion distance) and easy to fix.
- the porous matrix is e.g. a collagen matrix or consists of another physiologically acceptable material (e.g., as described above).
- the carrier matrix can be in the form of a thread structure or a network as defined above. In one embodiment, all materials of the patch are degradable in the body.
- the patch may further contain all or part of myocardial cells differentiated cells or other differentiated cells occurring in the heart.
- the patch may further contain substances that promote differentiation of the stem cells into cardiomyocytes, and / or pharmaceutical agents, e.g. to suppress a rejection reaction.
- the term "bidirectionally transformable" as used herein means that the patch is designed so that the cells contained in this patch, in particular stem cells, can come into contact with cells of the adjacent tissue or cells released on both sides, and thereby inducing or stimulating transformation / differentiation of the stem cells to the desired cell type.
- the patch is placed between the broad back muscle (latissimus dorsi muscle) and the epicardial myocardium (see FIG. 3). Then, the cells of the myocardium or substances released therefrom can induce a differentiation of the heart cells arranged in the patch stem cells to cardiac cells, especially heart muscle cells.
- the tissue of the back muscle can on the one hand provide the cells of the patch with nutrients and on the other hand induce a transformation of the backside arranged stem cells to vascular cells, eg endothelial cells, etc., or allow an immigration of corresponding cells into the patch, so that A new formation of capillaries in the patch or the adjacent tissue can take place.
- hypercapillarization of the dorsal muscle sheath with an intact muscle fascia is additionally induced in the patient by intermittent transcutaneous electrostimulation (eg by glued-on stimulation electrodes).
- the stem cells are injected into the (preferably hypercapillarized) muscle tissue (M. latissimus dorsi) itself, which wraps around the heart. They develop there and are transformed by substances of the adjacent injured myocardial surface (and / or supplied exogenous differentiation factors) into myocardial cells.
- the vascular system of the skeletal muscle then becomes the vascular system of the contracting myocardial patch.
- An implanted muscle pacemaker that electrostimulates the patch could also induce fiber transformation of the muscle fibers of skeletal muscle into pure oxygen-dependent type I fibers.
- type I fibers do not survive long-term stimulation and would eventually eliminate them Skeletal muscle fibers lead.
- a myocardial patch with its own vascular supply would be the result.
- the adult stem cells used are human stem cells which have been isolated from pancreatic tissue.
- pancreatic stem cells were cocultivated with small pieces of human heart muscle obtained from heart valve surgery. After a contact time of 48 hours, the myocardium was removed and stem cells were maintained in culture for a further 2 to 4 days and 2 weeks, respectively, to examine the influence of the myocardium on cardiomyocyte differentiation. Thereafter, the various methods, including immunocytochemistry of sarcomeres and cardiac-specific troponin I, semiquantitative RT-PCR analysis for alpha-actin and troponin T2 and electron microscopic examination were used to detect cardiomyocytes.
- Myocardium for cocultivation can be obtained by biopsies from the cardiac septum, which are already routinely used to detect tissue rejection after heart transplantation.
- the method according to the invention which can easily and conveniently prepare a large number of contractible cardiomyocytes, could be of importance for general myocardial regeneration and, in particular, for contractile myocardial patches.
- FIGS 1 and 2 show the results of various detection methods for cardiomyocytes.
- Fig. Ib Immunocytochemical visualization of sarcomeres (red) in transformed adult pancreatic stem cells (blue nuclei) in contact with human myocardium (M) for 2 days. A decreasing gradient from M to the periphery can be observed.
- Fig. Ic Gene expression analysis with the cardiac-specific PCR primers for the target genes ⁇ -actin and troponin T2 isoform-1 demonstrates a greater increase of muscle cell-specific molecules in co-cultured cells (CEpan 3b, human pancreatic stem cells; P14, passage 14, HEp -2, human carcinogenic cell line, h-heart cDNA, human heart cDNA).
- Fig. 2a, b Human pancreatic adult stem cells with immunocytochemical staining for cardiac-specific troponin I without contact with human myocardium (a) and after a two-day contact with human myocardium (b). A clear example of the Exis- Dementia of heart-specific troponin I in transformed cells is demonstrated.
- Fig. 2c, d Various stages of cardiomyocytes transformed from adult pancreatic stem cells are shown in the electron micrographs four days after 48 hours of contact with biopsies of human myocardium. Myofilaments and structures of partial (c) and complete (d) development of the glossy stripes are shown. Vesicles organized in lines ( Figure 2c, arrows) are considered as cross-sections of a premature status of the sarcoplasmic reticulum.
- FIG. 3 shows the placement of a biodirectionally transformable stem cell patch (BTS) between the myocardium and the broad dorsal muscle (latissimus dorsi muscle) for myocardial regeneration.
- BTS biodirectionally transformable stem cell patch
- FIG. 4 shows the growth of glandular stem cell thread structures.
- pancreatic tissue The source of human pancreatic tissue was healthy tissue removed for pancreatic surgery for cancer or inflammatory disease for safety reasons. The tissue was obtained in physiological saline. From this, pancreatic acini were isolated as already described (DE 10328280, Orlic et al., Nature 410: 701-705).
- the acini were centrifuged and further purified by washing in Dulbecco's modified Eagle's medium (DMEM, Gibco, Germany) supplemented with 20% fetal calf serum (FCS) equilibrated with carbogen and adjusted to pH 7.4. The washing procedure (centrifugation, aspiration, resuspension) was repeated 5 times.
- the acini were resuspended in DMEM and cultured at 37 ° C in a humidified atmosphere with 5% CO 2 . After 1 to 2 days of culture, spindle-shaped cells were observed surrounding the outer margins of the pancreatic acini. Differentiated acinar cells were removed with each medium exchange.
- pancreatic stem cells were cultured by trypsin treatment, counted and reseeded at a density of 2.4 x 10 5 cells / cm 2 . This procedure was repeated until sufficient cells were available. As already shown, no changes of the stem cells take place during the passages (checked by staining). Therefore, we used passages 14 and 4 for further differentiation.
- the stimulation of differentiation into cardiomyocytes was achieved by cocultivation of the primary cells with 5 pieces of myocardium (4 x 4 x 4 mm) for 2 days.
- the tissue (mitral papillary muscle or auriculum) was obtained in heart valve replacement surgery and transported in physiological saline.
- the heart muscle pieces were placed at the bottom of the culture vessels for 3 hours until the primary cells (1 x 10 6 ) were applied. After 48 hours were removed the heart muscle pieces and further cultured the stem cells as described above. The cells were then subjected to passage each time confluency was reached. Immunocytochemical analyzes were performed directly 48 hours after treatment. To study the long-term effects of differentiation, cells were harvested 17 days after treatment for PCR analysis.
- Fig. Ia The cell layer was washed with the less nutritious phosphate buffered saline (PBS) and mechanically partially lifted off the bottom of the culture with a scraper. Contracting regions were then documented on a video.
- PBS phosphate buffered saline
- biopsies were cultured as described above, but without pancreatic stem cells. After 2 days no growing cells could be detected.
- Myocardium (M) performed by four different patients.
- Stem cells were co-cultured with myocardial biopsies for 48 hours and cultured for 2 to 4 days after myocardial removal. Thereafter, the samples were rinsed twice with PBS and dried in air at room temperature for 24 hours and then fixed by pure acetone for 10 minutes at -20 ° C, rinsed again with TBS buffer for 2 x 5 minutes and with 10% RPMI 1640 AB-serium preincubated. Monoclonal antitroponin I antibodies (Cone 2d5, Biozal 1:25) were used as primary antibodies for 60 minutes.
- Total cell RNA was synthesized using a nucleo-spin RNA
- RNA samples (Macherey-Nagel, Düren, Germany) isolated. 0.5 ⁇ g of total RNA was reverse transcribed into cDNA using reverse transcriptase Superscript II RNase H ⁇ (RT, Invitrogen) and oligo dT primers (Invitrogen) according to the manufacturer's instructions. The PCR reactions were performed in 50 ⁇ l reaction volume using Taq DNA polymerase (MBI Fermentas). The reactions were carried out for 38 cycles. A control run of RNA without reverse transcription was performed to check for contamination with genomic DNA and gave no bands. To normalize the cDNA concentration in different RT samples we measured the relative expression of GAPDH as a representative control of an internal housekeeping gene.
- FIG. 2 cd The electron microscopic examination (FIG. 2 cd) shows cells with a number of contractile fibrils after 48 hours of contact of adult pancreatic stem cells with human myocardium and another 4 days differentiation. Furthermore, various stages of glossy stripes were observed. currency 2c, the glossy strip is well differentiated in FIG. 2d as in mature tissue. After a gloss stripe is found only in heart muscle, these findings also prove a differentiation of adult human stem cells into cardiomyocytes.
- the stem cells are seeded in petri dishes at a density of 1 ⁇ 10 3 and cultured for 24 hours in DMEM (containing 10% FCS and 1% penicillin / streptomycin) until they adherently adhere to the bottom of the culture dishes. The cells are then cultured for 24 hours in a differentiation medium containing:
- the cells are seeded in petri dishes at a density of 1 x 10 3 and cultured directly for 48 h with a differentiation medium containing:
- cardiogenol solution 5 mg cardiogenol are dissolved in 4.75 ml DMSO.
- the cells are incubated for 7 days in the following differentiation medium: DMEM medium
- Cardiomyocytes are sown on a culture bottle so that they completely overgrow the bottom of the bottle. Then, stem cells (labeled, for example, with ⁇ -galactosidase) are added to the cells at a density of 1 ⁇ 10 3 and cocultured for 14 days. Based on the labeled stem cells, the number of cells differentiated in cardiomyocytes can be determined, for example, by FACS analysis.
- Cardiomyocytes are placed in a cell culture cage for 14 days to freshly seeded pancreatic stem cells.
- the cardiomyocytes will release various substances that promote the differentiation of stem cells into cardiomyocytes.
- a fusion with co-cultured cells can be ruled out and the cells need not be marked beforehand.
- Stem cells from exocrine glands of humans and goats are sown in different passages on resorbable threads and nets. These threads and nets are for example made of Vicryl (sterile packaged by Ethicon) and are previously coated with 1% gelatin. This is followed by sowing of the stem cells in DMEM supplemented with 10% FCS. The stem cells accumulate on and in the microstructures of the threads and nets after only a few hours, and can then be stained with various stains, e.g. Nuclear staining, represent.
- various stains e.g. Nuclear staining
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007034679A DE102007034679A1 (de) | 2007-07-25 | 2007-07-25 | Materialzusammensetzungen, welche aus exokrinem Drüsengewebe erhaltene adulte Stammzellen enthalten, insbesondere zur Verwendung in der Regenerationsmedizin, z.B. zur Wiederherstellung von verletztem oder geschädigtem Myokardgewebe |
PCT/EP2008/005680 WO2009012901A2 (de) | 2007-07-25 | 2008-07-11 | Materialzusammensetzungen, welche aus exokrinem drüsengewebe erhaltene adulte stammzellen enthalten, insbesondere zur verwendung in der regenerationsmedizin, z. b. zur wiederherstellung von verletztem oder geschädigtem myokardgewebe |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2167109A2 true EP2167109A2 (de) | 2010-03-31 |
Family
ID=40149671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08784719A Withdrawn EP2167109A2 (de) | 2007-07-25 | 2008-07-11 | Materialzusammensetzungen, welche aus exokrinem drüsengewebe erhaltene adulte stammzellen enthalten, insbesondere zur verwendung in der regenerationsmedizin, z. b. zur wiederherstellung von verletztem oder geschädigtem myokardgewebe |
Country Status (4)
Country | Link |
---|---|
US (2) | US20100291211A1 (de) |
EP (1) | EP2167109A2 (de) |
DE (1) | DE102007034679A1 (de) |
WO (1) | WO2009012901A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9317179B2 (en) | 2007-01-08 | 2016-04-19 | Samsung Electronics Co., Ltd. | Method and apparatus for providing recommendations to a user of a cloud computing service |
US7937451B2 (en) | 2007-01-08 | 2011-05-03 | Mspot, Inc. | Method and apparatus for transferring digital content from a computer to a mobile handset |
AT511441B1 (de) | 2011-09-21 | 2012-12-15 | Univ Wien Tech | Triazin-derivate als differenzierungsbeschleuniger |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002057430A2 (en) * | 2001-01-20 | 2002-07-25 | Cardion Ag | Pluripotent adult stem cells derived from regenerative tissue |
IL158368A0 (en) * | 2001-04-13 | 2004-05-12 | Anterogen Co Ltd | Methods and reagents for cell transplantation |
WO2003091398A2 (en) * | 2002-04-23 | 2003-11-06 | Roger Williams Hospital | Compositions and methods for stem cell delivery |
AU2003286425A1 (en) * | 2002-12-05 | 2004-06-23 | Cardio Incorporated | Layered bioresorbable implant |
US20040197375A1 (en) * | 2003-04-02 | 2004-10-07 | Alireza Rezania | Composite scaffolds seeded with mammalian cells |
DE10362002B4 (de) * | 2003-06-23 | 2006-10-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Adulte pluripotente Stammzellen |
DE10328280B3 (de) | 2003-06-23 | 2005-01-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Herstellung adulter pluripotenter Stammzuellen |
US8703121B2 (en) * | 2003-06-27 | 2014-04-22 | DePuy Synthes Products, LLC | Postpartum-derived cells for use in treatment of disease of the heart and circulatory system |
US9375514B2 (en) * | 2004-05-21 | 2016-06-28 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Multicellular tissue and organ culture systems |
DE102006003996A1 (de) * | 2006-01-27 | 2007-08-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Herstellung autonom kontrahierender Herzmuskelzellen aus adulten Stammzellen, insbesondere humanen adulten Stammzellen |
JP4802059B2 (ja) | 2006-07-27 | 2011-10-26 | 株式会社エンプラス | 電気部品用ソケット |
EP2079831A2 (de) * | 2006-11-07 | 2009-07-22 | Keck Graduate Institute | Angereicherte stammzell- und vorläuferzellpopulationen sowie verfahren zur herstellung und verwendung derartiger populationen |
-
2007
- 2007-07-25 DE DE102007034679A patent/DE102007034679A1/de not_active Ceased
-
2008
- 2008-07-11 WO PCT/EP2008/005680 patent/WO2009012901A2/de active Application Filing
- 2008-07-11 US US12/670,587 patent/US20100291211A1/en not_active Abandoned
- 2008-07-11 EP EP08784719A patent/EP2167109A2/de not_active Withdrawn
-
2012
- 2012-11-13 US US13/675,133 patent/US8992978B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO2009012901A3 * |
Also Published As
Publication number | Publication date |
---|---|
US8992978B2 (en) | 2015-03-31 |
US20100291211A1 (en) | 2010-11-18 |
WO2009012901A2 (de) | 2009-01-29 |
DE102007034679A1 (de) | 2009-01-29 |
WO2009012901A3 (de) | 2009-11-12 |
US20130142860A1 (en) | 2013-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60121450T2 (de) | Mittels gewebetechnologie hergestellte dezellularisierte gegenstände und gewebe | |
DE69831957T2 (de) | Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen | |
EP1265986B1 (de) | Verfahren zur in vitro-herstellung von dreidimensionalem, vitalem knorpel- oder knochengewebe | |
EP2446892B1 (de) | Isolierte adulte pluripotente Stammzellen | |
EP1747264B1 (de) | Multizelluläre gewebe- und organkultursysteme | |
CN1852973A (zh) | 从活检分离和扩充心脏干细胞的方法 | |
DE102007008650B4 (de) | Zellen zur Therapie des Herzens | |
DE112007000030T5 (de) | Verfahren zur Isolierung einer Haarfollikelstammzelle und Zusammensetzung für die Haarreproduktion | |
EP1976979B1 (de) | Verfahren zur herstellung autonom kontrahierender herzmuskelzellen aus adulten stammzellen, insbesondere humanen adulten stammzellen | |
EP2167109A2 (de) | Materialzusammensetzungen, welche aus exokrinem drüsengewebe erhaltene adulte stammzellen enthalten, insbesondere zur verwendung in der regenerationsmedizin, z. b. zur wiederherstellung von verletztem oder geschädigtem myokardgewebe | |
DE102005017000B4 (de) | Verfahren zur Herstellung eines Gewebetransplantatkonstruktes zur Rekonstruktion eines menschlichen oder tierischen Organs | |
CN107250348B (zh) | 使用表达lgr4、lgr5和lgr6的上皮干细胞在组织应用中开发和使用最小极性化功能细胞微聚集体单元的方法 | |
JPWO2005035739A1 (ja) | 再生治療システム | |
WO2005001073A1 (de) | Verfahren zur differenzierung von stammzellen in zellen, die ein pankreatisches hormon produzieren | |
EP2475766A1 (de) | Spontan kontrahierende fischzellaggregate, deren verwendung und verfahren zu deren erzeugung | |
EP1749089B1 (de) | Verfahren und vorrichtungen zum kultivieren von stammzellen | |
EP2755666B1 (de) | Verfahren zur herstellung eines biologischen gewebekonstrukts und verwendung spezifisch gewonnener autologer zellen und dessen medizinische verwendung | |
DE102004025081B4 (de) | Multizelluläre Gewebe- und Organkultursysteme | |
CN115770324A (zh) | 一种促进神经再生的活体静电纺丝支架的制备方法 | |
EP2559755A2 (de) | Verfahren zur herstellung einer kardiomyozytenmatrix | |
EP1550716A1 (de) | Verfahren zur Herstellung dreidimensionaler trägerfreier Gewebestrukturen und nach diesem Verfahren hergestellte Gewebestrukturen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100111 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20110112 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 35/55 20150101ALI20150220BHEP Ipc: A61K 35/37 20150101AFI20150220BHEP Ipc: C12N 5/074 20100101ALI20150220BHEP Ipc: A61P 9/00 20060101ALI20150220BHEP Ipc: A61P 43/00 20060101ALI20150220BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150520 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20151001 |